512 related articles for article (PubMed ID: 32838726)
1. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
[TBL] [Abstract][Full Text] [Related]
2. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity and structural features of Ru(II)/phosphine/amino acid complexes.
Dos Santos ER; Graminha AE; Schultz MS; Correia I; Selistre-de-Araújo HS; Corrêa RS; Ellena J; Lacerda EPS; Pessoa JC; Batista AA
J Inorg Biochem; 2018 May; 182():48-60. PubMed ID: 29433005
[TBL] [Abstract][Full Text] [Related]
5. Ru(II)-Naphthoquinone complexes with high selectivity for triple-negative breast cancer.
Oliveira KM; Peterson EJ; Carroccia MC; Cominetti MR; Deflon VM; Farrell NP; Batista AA; Correa RS
Dalton Trans; 2020 Nov; 49(45):16193-16203. PubMed ID: 32329497
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antitumor activity of a novel carbonyl ruthenium compound, the ct-[RuCl(CO)(dppb)(bipy)]PF-6[dppb=1,4-bis(diphenylphosphine)butane and bipy=2,2'-bipyridine].
Carnizello AP; Barbosa MI; Martins M; Ferreira NH; Oliveira PF; Magalhães GM; Batista AA; Tavares DC
J Inorg Biochem; 2016 Nov; 164():42-48. PubMed ID: 27613330
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic Ruthenium(II) Complexes Containing a Dangling Pyridine: Selectivity for Diseased Cells Mediated by pH-Dependent DNA Binding.
Sangeetha S; Murali M
Inorg Chem; 2022 Feb; 61(6):2864-2882. PubMed ID: 35099196
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of Ru(II) piano-stool complexes with chloroquine and chelating ligands against breast and lung tumor cells: Interactions with DNA and BSA.
Colina-Vegas L; Villarreal W; Navarro M; de Oliveira CR; Graminha AE; Maia PIDS; Deflon VM; Ferreira AG; Cominetti MR; Batista AA
J Inorg Biochem; 2015 Dec; 153():150-161. PubMed ID: 26277415
[TBL] [Abstract][Full Text] [Related]
9. Cis-[RuCl(BzCN)(N-N)(P-P)]PF6 complexes: Synthesis and in vitro antitumor activity: (BzCN=benzonitrile; N-N=2,2'-bipyridine; 1,10-phenanthroline; P-P=1,4-bis(diphenylphosphino) butane, 1,2-bis(diphenylphosphino)ethane, or 1,1'-(diphenylphosphino)ferrocene).
Pereira Fde C; Lima BA; de Lima AP; Pires WC; Monteiro T; Magalhães LF; Costa W; Graminha AE; Batista AA; Ellena J; Siveira-Lacerda Ede P
J Inorg Biochem; 2015 Aug; 149():91-101. PubMed ID: 25873134
[TBL] [Abstract][Full Text] [Related]
10. Non-mutagenic Ru(ii) complexes: cytotoxicity, topoisomerase IB inhibition, DNA and HSA binding.
da Silva MM; de Camargo MS; Correa RS; Castelli S; De Grandis RA; Takarada JE; Varanda EA; Castellano EE; Deflon VM; Cominetti MR; Desideri A; Batista AA
Dalton Trans; 2019 Oct; 48(39):14885-14897. PubMed ID: 31555783
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A
Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the biological potential of ruthenium(II) complexes with cinnamic acid.
Graminha AE; Honorato J; Dulcey LL; Godoy LR; Barbosa MF; Cominetti MR; Menezes AC; Batista AA
J Inorg Biochem; 2020 May; 206():111021. PubMed ID: 32163810
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic activity of Ru(II)/DPEPhos/N,S-mercapto complexes (DPEPhos = bis-[(2-diphenylphosphino)phenyl]ether).
Grawe GF; Oliveira KM; Leite CM; de Oliveira TD; Costa AR; Moraes CAF; Honorato J; Cominetti MR; Castellano EE; Correa RS; Machado SP; Batista AA
J Inorg Biochem; 2023 Jul; 244():112204. PubMed ID: 37004320
[TBL] [Abstract][Full Text] [Related]
14. A novel ruthenium(ii) gallic acid complex disrupts the actin cytoskeleton and inhibits migration, invasion and adhesion of triple negative breast tumor cells.
Graminha AE; Honorato J; Correa RS; Cominetti MR; Menezes ACS; Batista AA
Dalton Trans; 2021 Jan; 50(1):323-335. PubMed ID: 33305766
[TBL] [Abstract][Full Text] [Related]
15. Ruthenium(II) Phosphine/Mercapto Complexes: Their in Vitro Cytotoxicity Evaluation and Actions as Inhibitors of Topoisomerase and Proteasome Acting as Possible Triggers of Cell Death Induction.
Ribeiro GH; Guedes APM; de Oliveira TD; de Correia CRSTB; Colina-Vegas L; Lima MA; Nóbrega JA; Cominetti MR; Rocha FV; Ferreira AG; Castellano EE; Teixeira FR; Batista AA
Inorg Chem; 2020 Oct; 59(20):15004-15018. PubMed ID: 32997499
[TBL] [Abstract][Full Text] [Related]
16. Pro-apoptotic activity of ruthenium 1-methylimidazole complex on non-small cell lung cancer.
Dias JSM; Silva HVR; Ferreira-Silva GÁ; Ionta M; Corrêa CC; Almeida F; Colina-Vegas L; Barbosa MIF; Doriguetto AC
J Inorg Biochem; 2018 Oct; 187():1-13. PubMed ID: 30015231
[TBL] [Abstract][Full Text] [Related]
17. New ruthenium complexes containing salicylic acid and derivatives induce triple-negative tumor cell death via the intrinsic apoptotic pathway.
Graminha AE; Popolin C; Honorato de Araujo-Neto J; Correa RS; de Oliveira KM; Godoy LR; Vegas LC; Ellena J; Batista AA; Cominetti MR
Eur J Med Chem; 2022 Dec; 243():114772. PubMed ID: 36191406
[TBL] [Abstract][Full Text] [Related]
18. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA
Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of ruthenium-N,N-disubstituted-N'-acylthioureas complexes.
de Oliveira TD; Plutín AM; Luna-Dulcey L; Castellano EE; Cominetti MR; Batista AA
Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111106. PubMed ID: 32600709
[TBL] [Abstract][Full Text] [Related]
20. Lapachol in the Design of a New Ruthenium(II)-Diphosphine Complex as a Promising Anticancer Metallodrug.
Oliveira KM; Honorato J; Demidoff FC; Schultz MS; Netto CD; Cominetti MR; Correa RS; Batista AA
J Inorg Biochem; 2021 Jan; 214():111289. PubMed ID: 33137682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
